| You are here: Home: BCU 7|2003: Richard
M Elledge, MD: Select publications
Select publications
Publications discussed by Dr Elledge
Bundred NJ et al. Fulvestrant, an estrogen
receptor downregulator, reduces cell turnover index more effectively
than tamoxifen. Anticancer
Res 2002;22(4):2317-9. Abstract
Carlson RW. Sequencing of endocrine therapies
in breast cancer - integration
of recent data. Breast Cancer Res Treat 2002;75 Suppl 1:S27-32;
discussion S33-5. Abstract
Howell A et al. Fulvestrant, formerly ICI
182,780, is as effective as anastrozole in postmenopausal women
with advanced breast cancer progressing after prior endocrine
treatment. J Clin Oncol 2002;20(16):3396-403. Abstract
Howell A et al. Fulvestrant versus anastrozole
for the treatment of advanced breast cancer: Survival analysis
from a phase III trial. Proc ASCO 2003;Abstract 178.
Jones SE. A new estrogen receptor antagonist - an overview of
available data. Breast Cancer Res Treat 2002;75 (Suppl 1):S19-21;
discussion S33-5. Abstract
Mauriac L et al. Fulvestrant (Faslodex) versus
anastrozole for the second-line treatment of advanced breast
cancer in subgroups of postmenopausal women with visceral and
non-visceral metastases: Combined results from two multicentre
trials. Eur J Cancer 2003;39(9):1228-33.
Abstract
Morris C, Wakeling A. Fulvestrant ('Faslodex') - a new treatment
option for patients progressing on prior endocrine therapy. Endocr
Relat Cancer 2002;9(4):267-76. Abstract
Osborne CK et al. Double-blind, randomized
trial comparing the efficacy and tolerability of fulvestrant
versus anastrozole in postmenopausal women with advanced breast
cancer progressing on prior endocrine therapy: Results of a North
American trial. J Clin
Oncol 2002;20(16):3386-95. Abstract
Parker LM. Sequencing of hormonal therapy
in postmenopausal women with metastatic breast cancer. Clin Ther 2002;24(Suppl C):C43-57.Abstract
Parker LM et al. Greater duration of response
in patients receiving fulvestrant ('Faslodex') compared with
those receiving anastrozole ('Arimidex'). Proc ASCO2002; Abstract 160.
Piccart M et al. Oestrogen receptor downregulation:
An opportunity for extending the window of endocrine therapy
in advanced breast cancer. Ann Oncol 2003;14(7):1017-25. Abstract
Pritchard KI. Endocrine therapy of advanced
disease: Analysis and implications of the existing data. Clin
Cancer Res 2003;9(1 Pt 2):460S-7S. Abstract
Robertson JF et al. Pharmacokinetics of a
single dose of fulvestrant prolonged-release intramuscular injection
in postmenopausal women awaiting surgery for primary breast cancer. Clin
Ther 2003;25(5):1440-52. Abstract
Robertson JF, Harrison MP. Equivalent single-dose
pharmacokinetics of two different dosing methods of prolonged-release
fulvestrant ('Faslodex') in postmenopausal women with advanced
breast cancer. Cancer Chemother Pharmacol2003. Abstract
Sommer A et al. Studies on the development
of resistance to the pure antiestrogen Faslodex in three human
breast cancer cell lines. J Steroid Biochem Mol Biol2003;85(1):33-47. Abstract
Steger GG et al. Fulvestrant beyond the second
hormonal treatment line in metastatic breast cancer. Proc
ASCO 2003;Abstract 78.
Vergote I et al. Postmenopausal women who
progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast
Cancer Res Treat 2003;79(2):207-11. Abstract
Wardley AM. Fulvestrant: A review of its
development, pre-clinical and clinical data. Int J Clin Pract 2002;56(4):305-9. Abstract
Watanabe T et al. Fulvestrant provides clinical
benefit to postmenopausal women with metastatic breast cancer
who have relapsed on prior antiestrogen therapy: A Japanese study. Proc
ASCO 2003;Abstract 274.
|
